NCBIO advocates for North Carolina’s life sciences industry at the state and national levels. In North Carolina, the Organization represents its members at the North Carolina General Assembly and before state courts, regulatory agencies and executive branch policy leaders.
At the national level, NCBIO works with the national Biotechnology Innovation Organization (BIO), the Pharmaceutical Research & Manufacturers of America (PhRMA), AdvaMed and the Medical Device Manufacturers Association (MDMA) to support appropriate federal policies and to keep members of North Carolina's congressional delegation informed as to industry needs and priorities.
BIO, NCBIO and Other Groups Oppose Proposed Changes to Medicare Part B
A proposed rule released on March 8 by the Centers for Medicare & Medicaid Services (CMS) would put patient access and care quality at risk for millions of Medicare patients through sweeping, aggressive changes to payment policy for drugs covered under Part B.
Medicare Part B covers a subset of outpatient prescription drugs, used by patients with complex conditions who currently have few or no other treatment options. Maintaining access to medicines under Medicare Part B is crucial for vulnerable patients who suffer from serious illnesses such as cancer, cerebral palsy, and immune deficiency disease.
NCBIO believes that CMS’s changes, which are published as a demonstration model by the Center for Medicare and Medicaid Innovation represent a significant over-reach of CMS’ authority and would reduce payment for many providers and, in later phases, rely on centralized government determinations of value. More than 300 organizations have joined together to oppose the proposal. The groups, including NCBIO, are writing the Congress asking that the rule be withdrawn.